Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Astellas Pharma

- PMLiVE

Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics

The company will gain the rights to use 4DMT’s gene therapy vector for at least one target

- PMLiVE

Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn

The transaction includes the Swiss drugmaker’s anti-inflammatory eye drop Xiidra

- PMLiVE

Astellas to acquire Iveric Bio for approximately $5.9bn

The deal includes the US drugmaker’s lead candidate for geographic atrophy

- PMLiVE

Positive results for Astellas’ zolbetuximab in gastric cancer published in The Lancet

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Bayer's Eylea remains the drug to beat, however

AstraZeneca AZ

AZ makes gene therapy move with 4DMT alliance

The new partnership will focus on creating an AAV for lung disease

- PMLiVE

The power of pharma businesses to drive social change

The importance of CSR programmes

- PMLiVE

Astellas: Ten years young

Ken Jones and Sef Kurstjens on the company's progress and plans

- PMLiVE

Pfizer to form specialty drugs unit after Allergan takeover

Will merge its consumer portfolio with Allergan's ophthalmology and aesthetics brands

- PMLiVE

The BMJ weighs in on Avastin/Lucentis debate

The UK’s leading medical journal says Avastin should be used for wet AMD to cut costs

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

- PMLiVE

New eye indication for Allergan’s Ozurdex

EU approval extends the drug's use to diabetic macular oedema

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links